Want to see IN:NOVARTIND full AI Analyst Report?
Top Page
Novartis India Limited
(NOVARTIND)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹2,283.00
Action:N/A
Date:09/22/26
The score is driven primarily by strong financial strength (especially a very low-debt balance sheet) and a clear positive price trend with supportive momentum. These strengths are tempered by a high valuation (P/E 50.56) and a history of cash flow and revenue variability.
Positive Factors
Very low financial leverage
An almost debt-free balance sheet materially reduces financial risk and interest-related pressure on earnings. It gives Novartis India flexibility to sustain operations, fund commercialization, and absorb weaker periods without depending heavily on refinancing or additional borrowing.
Negative Factors
Uneven revenue growth
The uneven revenue trajectory shows that growth has not been consistently established across the full period. Although the latest rebound is encouraging, repeated declines can make planning less predictable and may limit confidence that recent momentum will translate into durable expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low financial leverage
An almost debt-free balance sheet materially reduces financial risk and interest-related pressure on earnings. It gives Novartis India flexibility to sustain operations, fund commercialization, and absorb weaker periods without depending heavily on refinancing or additional borrowing.
Read all positive factors
Novartis India Limited (NOVARTIND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹48.56B
Dividend Yield1.27%
Average Volume (3M)16.57K
Price to Earnings (P/E)51.7
Beta (1Y)0.07
Revenue Growth5.42%
EPS Growth-4.87%
CountryIN
Employees59
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)39.61
Shares Outstanding24,690,796
10 Day Avg. Volume4,851
30 Day Avg. Volume16,574
Financial Highlights & Ratios
PEG Ratio-3.36
Price to Book (P/B)2.93
Price to Sales (P/S)6.76
P/FCF Ratio28.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novartis India Limited Business Overview & Revenue Model
Company Description
Novartis India Limited, an Indian healthcare enterprise, provides a diverse range of pharmaceutical solutions. Its offerings include branded medications for conditions related to bone and pain management, calcium supplementation, women's health (g...
How the Company Makes Money
Novartis India Limited primarily makes money by commercializing pharmaceutical products in India. Its core revenue stream is the sale of branded prescription medicines to customers such as hospitals, pharmacies, distributors, and other healthcare ...
Novartis India Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.71B | 3.54B | 3.56B | 3.35B | 3.79B | 4.00B |
| Gross Profit | 1.41B | 1.33B | 1.53B | 1.09B | 1.22B | 785.50M |
| EBITDA | 1.20B | 941.00M | 968.20M | 1.27B | 1.23B | 106.60M |
| Net Income | 977.70M | 931.80M | 1.01B | 851.90M | 1.03B | -37.20M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.78B | 9.48B | 9.25B | 9.83B | 9.58B |
| Cash, Cash Equivalents and Short-Term Investments | 6.68B | 6.58B | 6.37B | 5.85B | 5.54B | 5.16B |
| Total Debt | 0.00 | 32.10M | 50.60M | 69.70M | 215.10M | 240.10M |
| Total Liabilities | -8.18B | 1.60B | 1.63B | 1.80B | 2.07B | 2.66B |
| Stockholders Equity | 8.18B | 8.18B | 7.85B | 7.45B | 7.76B | 6.92B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 843.60M | 745.70M | 1.13B | 444.90M | 381.70M |
| Operating Cash Flow | 0.00 | 847.00M | 745.70M | 1.13B | 448.00M | 386.70M |
| Investing Cash Flow | 0.00 | -203.40M | -33.10M | 331.30M | -1.53B | 870.40M |
| Financing Cash Flow | 0.00 | -639.30M | -641.50M | -1.21B | -304.80M | -356.30M |
Novartis India Limited Technical Analysis
Positive
―
Price Trends
1742.92
Positive
1586.43
Positive
1240.70
Positive
Market Momentum
63.83
Positive
55.16
Neutral
22.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NOVARTIND, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 2004.83, equal to the 50-day MA of 1742.92, and equal to the 200-day MA of 1240.70, indicating a neutral trend. The MACD of 63.83 indicates Positive momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 22.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NOVARTIND.
Novartis India Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹1.08T | 32.11 | ― | 2.16% | 1.85% | -37.51% | |
78 Outperform | ₹48.56B | 51.73 | ― | 1.27% | 5.42% | -4.87% | |
72 Outperform | ₹1.01T | 30.41 | ― | 0.66% | -0.92% | -41.75% | |
69 Neutral | ₹919.15B | 16.77 | ― | 0.88% | 28.19% | 49.25% | |
66 Neutral | ₹643.92B | 36.27 | ― | 0.22% | 32.94% | 138.54% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹147.82B | 88.14 | ― | 0.60% | 31.10% | -7.49% |
* General Sector Average
IN:NOVARTIND
Novartis India Limited
2,049.05
1,174.25
134.23%
IN:ASTRAZEN
AstraZeneca Pharma India Limited
5,983.25
-3,362.82
-35.98%
IN:CIPLA
Cipla Ltd
1,343.00
-156.72
-10.45%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,209.15
-32.13
-2.59%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,288.95
328.50
16.76%
IN:LUPIN
Lupin Limited
2,035.00
124.21
6.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.